JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $77
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero maintains an Overweight rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $78 to $77.

March 07, 2024 | 7:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Cytokinetics but lowers the price target from $78 to $77.
The adjustment in price target by JP Morgan reflects a slight change in valuation expectation for Cytokinetics. While the Overweight rating is maintained, indicating a positive outlook on the stock, the reduction in price target suggests a minor recalibration of future price expectations. This could lead to a neutral short-term impact on the stock as the market digests the slight adjustment in valuation perspective.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100